News >

Pembrolizumab Shows Promise in Small Cell Lung Cancer

Jason Harris
Published: Thursday, Aug 31, 2017

Patrick Ott, MD, PhD

Patrick Ott, MD, PhD
Pembrolizumab (Keytruda) induced an overall response rate (ORR) of 33% in patients with extensive-stage small cell lung cancer (SCLC), according to findings from the open-label, phase Ib KEYNOTE-028 trial published in the Journal of Clinical Oncology.

Pembrolizumab has FDA approved indications in melanoma, non–small cell lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high cancer.
Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib keynote-028 study [published online August 16, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.72.5069.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x